|
|
Volumn 26, Issue 9, 2008, Pages 957-959
|
|
Actemra poised to launch IL-6 inhibitors
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ATLIZUMAB;
C 326;
CNTO 136;
CNTO 328;
CR5 18;
ETANERCEPT;
GLYCOPROTEIN GP 130;
INFLIXIMAB;
INTERLEUKIN 6;
INTERLEUKIN 6 RECEPTOR;
INTERLEUKIN 6 RECEPTOR INHIBITOR;
METHOTREXATE;
MONOCLONAL ANTIBODY;
PLACEBO;
PPI 2458;
REGN 88;
RITUXIMAB;
UNCLASSIFIED DRUG;
ANEMIA;
ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA;
ANOREXIA;
CLINICAL TRIAL;
COOPERATION;
CYTOKINE PRODUCTION;
DECISION MAKING;
DRUG APPROVAL;
DRUG EFFECT;
DRUG EFFICACY;
DRUG MARKETING;
DRUG MECHANISM;
DRUG TREATMENT FAILURE;
FATIGUE;
FEVER;
GENETIC ENGINEERING;
HUMAN;
NOTE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SYMPTOM;
ANIMALS;
ANTI-INFLAMMATORY AGENTS;
ANTIBODIES, MONOCLONAL;
BIOTECHNOLOGY;
CHEMISTRY, PHARMACEUTICAL;
DRUG DESIGN;
DRUG INDUSTRY;
HUMANS;
IMMUNE SYSTEM;
INFLAMMATION;
INTERLEUKIN-6;
MICE;
|
|
EID: 51349134454
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0908-957 Document Type: Note |
|
Times cited : (29)
|
|
References (0)
|
